文献速递淋巴瘤

复发难治性霍奇金淋巴瘤基线代谢肿瘤体积的预后意义

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
PubMed 文献 · Blood · 2017-09-05

在复发/难治性霍奇金淋巴瘤的2期研究中,患者接受维布妥昔单抗联合增强型ICE的PET适应挽救治疗。多因素分析显示基线代谢肿瘤体积(bMTV)和难治性疾病是事件无生存(EFS)的独立预后因素,低bMTV且复发疾病者3年EFS达100%。

要点

  • 基线MTV(bMTV)和难治性疾病是复发/难治性霍奇金淋巴瘤EFS的独立预后因素。
  • 低bMTV(<109.5 cm3)且复发疾病者3年EFS为100%。
  • bMTV可改善移植前PET对EFS的预测能力。

核心结论

  • 在PET适应挽救治疗(维布妥昔单抗联合增强型ICE)的2期研究中,bMTV和难治性疾病是复发/难治性霍奇金淋巴瘤EFS的独立预后因素。
  • bMTV改善了移植前PET的预测能力。

研究设计与样本

  • 2期研究,纳入65例适合移植的复发/难治性霍奇金淋巴瘤患者(队列1 45例,队列2 20例)。
  • 患者接受2个(队列1)或3个(队列2)周期每周维布妥昔单抗;PET阴性(Deauville评分≤2)者直接行自体干细胞移植(ASCT),PET阳性者接受增强型ICE后行ASCT。
  • 基线、维布妥昔单抗后和增强型ICE后测量代谢肿瘤体积(MTV)和总病灶糖酵解,基线及维布妥昔单抗后测量血清细胞因子和趋化因子。

主要发现

  • 65例中49例(75%)达到完全缓解,64例进行ASCT。
  • 3年总生存率和EFS分别为95%和82%。
  • 多因素分析中EFS的预测因素为基线MTV(P < .001)和难治性疾病(P = .003)。
  • 低bMTV(<109.5 cm3)且复发疾病者3年EFS为100%。
  • 接受移植者中,bMTV和移植前PET独立预后;移植前PET阳性且低bMTV者3年EFS为86%。

临床怎么用

  • 作者认为未来研究应根据bMTV等风险因素对患者分层,以优化挽救治疗的疗效和耐受性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study of positron emission tomography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinical factors, quantitative PET assessments, and cytokine and chemokine values. Transplant-eligible patients with relapsed/refractory HL received 2 (cohort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative patients (Deauville score ≤2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive patients received augICE before ASCT. Serum cytokine and chemokine levels were measured at baseline and after BV. Metabolic tumor volume (MTV) and total lesion glycolysis were measured at baseline, after BV, and after augICE. Sixty-five patients enrolled (45, cohort 1; 20, cohort 2); 49 (75%) achieved complete response and 64 proceeded to ASCT. Three-year overall survival and event-free survival (EFS) were 95% and 82%, respectively. Factors predictive for EFS by multivariable analysis were baseline MTV (bMTV) (P < .001) and refractory disease (P = .003). Low bMTV (<109.5 cm3) and relapsed disease identified a favorable group (3-year EFS, 100%). For patients who received a transplant, bMTV and pre-ASCT PET were independently prognostic; 3-year EFS for pre-ASCT PET-positive patients with low bMTV was 86%. In this phase 2 study of PET-adapted therapy with BV and augICE for relapsed/refractory HL, bMTV and refractory disease were independent prognostic factors for EFS. Furthermore, bMTV improved the predictive power of pre-ASCT PET. Future studies should optimize efficacy and tolerability of salvage therapy by stratifying patients according to risk factors such as bMTV.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Moskowitz AJ, Schöder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017. PMID: 28874350. doi:10.1182/blood-2017-06-788877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。